Overview
ARA-290, also known as cibinetide, is a synthetic peptide derived from erythropoietin (EPO). Unlike EPO, ARA-290 does not stimulate red blood cell production (non-erythropoietic) but retains EPO's tissue-protective and anti-inflammatory properties. This makes it a potential therapeutic agent for conditions involving tissue damage and inflammation without the risks associated with increased red blood cell count.
ARA-290 binds to the innate repair receptor (IRR), which is a heteromer of the erythropoietin receptor (EPOR) and the CD131 subunit. This receptor is found on various tissues, including those of the nervous system and immune system. Activation of the IRR triggers downstream signaling pathways that promote cell survival, reduce inflammation, and enhance tissue repair.
ARA-290 has been studied for its potential in treating neuropathic pain, sarcoidosis, and other conditions characterized by inflammation and tissue damage. Its unique mechanism of action, which avoids erythropoiesis, offers a novel approach to managing these disorders.
Mechanism of Action
ARA-290 exerts its effects by selectively binding to the innate repair receptor (IRR). The IRR, a dimer of EPOR and CD131, activates intracellular signaling cascades upon ARA-290 binding, leading to the modulation of various cellular processes. One of the key pathways activated is the PI3K/Akt pathway, which promotes cell survival and inhibits apoptosis (programmed cell death).
Furthermore, ARA-290 modulates inflammatory responses by inhibiting the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. This anti-inflammatory effect contributes to the overall tissue-protective action of the peptide. It also promotes the production of anti-inflammatory mediators, further dampening the inflammatory response. By reducing inflammation and promoting cell survival, ARA-290 creates an environment conducive to tissue repair and regeneration.
Key Benefits
- Reduces neuropathic pain
- Promotes tissue repair
- Anti-inflammatory effects
- Neuroprotective properties
Research & Indications
Clinical trials have explored ARA-290's efficacy in treating neuropathic pain, particularly in patients with sarcoidosis-associated small fiber neuropathy. Studies have demonstrated significant reductions in pain scores and improvements in nerve fiber density. It has also been investigated for its potential in treating other inflammatory conditions, such as diabetic neuropathy and critical limb ischemia.
Preclinical research suggests that ARA-290 may have broader applications in conditions involving tissue damage and inflammation, including wound healing, cardiovascular diseases, and neurodegenerative disorders. However, further clinical trials are needed to fully elucidate its therapeutic potential in these areas.
Dosing Protocols
Disclaimer: This information is not medical advice. Consult with a qualified healthcare professional before starting any peptide therapy.
Typical dosing for ARA-290:
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Neuropathic Pain Relief | 4-8 mg | 2-3 times weekly | SubQ |
Supplies Needed
For an 8-16 week protocol:
- Peptide Vials: 4-10 vials of 16mg each
- Insulin Syringes (U-100): 3-5 per week, 24-80 total
- Bacteriostatic Water: 2-3 × 10mL bottles
- Alcohol Swabs: One for vial + one for injection site daily
Side Effects & Safety
ARA-290 is generally well-tolerated in clinical trials. Common side effects may include mild injection site reactions, such as redness or swelling. Some individuals may experience transient flu-like symptoms. There are no known significant contraindications, but caution is advised in patients with a history of allergic reactions to peptides or related compounds.
Storage & Handling
Store lyophilized (unreconstituted) ARA-290 vials at 2-8°C (refrigerated). Once reconstituted with bacteriostatic water, the solution should be used within a few weeks and stored refrigerated. Avoid freezing reconstituted solutions.